as 09-05-2025 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
Market Cap: | 225.4M | IPO Year: | 2001 |
Target Price: | $13.50 | AVG Volume (30 days): | 67.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.45 | EPS Growth: | N/A |
52 Week Low/High: | $3.96 - $9.42 | Next Earning Date: | 11-06-2025 |
Revenue: | $33,302,000 | Revenue Growth: | -31.88% |
Revenue Growth (this year): | 0.96% | Revenue Growth (next year): | 51.71% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Raykov Rosty | FENC | Director | Sep 4 '25 | Sell | $8.92 | 10,000 | $89,200.00 | 51,086 |
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Zacks
2 months ago
GlobeNewswire
3 months ago
Simply Wall St.
4 months ago
GuruFocus.com
4 months ago
Thomson Reuters StreetEvents
4 months ago
MT Newswires
4 months ago
GlobeNewswire
4 months ago
GlobeNewswire
4 months ago
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.